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SHORT COMMUNICATION
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Pruritus is the chief symptom in many dermatologic and
systemic conditions and can be quite burdensome on a
patient’s health-related quality of life (HRQoL) (1–3).
ItchyQoL is a validated survey designed to assess the
pruritus-specific disease burden (4). Although it is understood that higher scores correspond to higher HRQoL
impact, the lack of clinical meaning for the scores has
limited its use outside of research. Such endeavors have
been performed for skin specific HRQoL measures such
as the Dermatology Life Quality index (DLQI) (4, 5) and
Skindex (6), where bands of scores are assigned a level
of HRQoL impairment. Defining bands of ItchyQoL
scores in terms of levels of itch-specific HRQoL impairment will provide clinicians with a better gauge of
both pruritus-specific burden of disease and the efficacy
of treatment. Researchers will be able to know whether
new interventions were able to make clinically, and not
just statistically, significant differences in itch burden
(7). In this pilot study, we utilized an existing dataset
and applied methods previously used in assigning clinical meaning for the DLQI to explore possible clinically
meaningful bands for the ItchyQoL (5, 8).
METHODS
Patients were recruited from the Atlanta VA Medical Center
outpatient dermatology clinic, with the only inclusion criteria
being a history of chronic (> 6 weeks duration) pruritus. Subjects completed multiple self-administered written surveys accessing HRQoL, including ItchyQoL and a Global Itch Severity
Question (GISQ).
ItchyQoL is a validated 22-question survey that assesses
pruritus-specific HRQoL impact on symptoms, functional limitations, and emotions (4). Each of the questions is scored 1–5 (1:
never; 2: rarely; 3: sometimes; 4: often; 5: all of the time) with
the sum forming the raw ItchyQol score with a range of 22–110.
A GISQ was used to anchor and thus provide clinical context
to the ItchyQoL results (7). GISQ is one question where the
respondents rate their itch on a scale of 0 to 10 with 0 being
no itch at all, and 10 being the worst itch ever experienced,
for the past 7 days.
Band formation: Raw ItchyQoL scores were divided into
10-point intervals (0–10, 11–20, 21–30, etc.), and the mean,
median, and mode of the GISQ scores of patients included in
each interval were calculated. Five potential raw ItchyQoL
band sets were created with effort to distribute the number of
patients as evenly as possible, but also restricting the number
of bands for ease of use. GISQ scores were divided into two
potential sets of intervals.
Correlations of each of the 5 potential ItchyQoL band sets
with each of the two proposed GISQ breakdowns was calculated
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using the Spearman Rank and Pearson correlation coefficients.
The kappa, both unweighted and weighted, coefficient of agree
ment was calculated for the banding system with the highest
Spearman and Pearson coefficient variables with p < 0.05 considered statistically significant (9). Analyses were performed
using SAS 9.2. The anchoring technique was modeled after
work done on the DLQI (10).

RESULTS
The majority of the 54 subjects were men (85%) and
Caucasian (79%). The mean ± SD age was 63.8 ± 15.5
years. The majority (75%) experienced pruritus most
or all of the time and nearly all (93%) had experienced
pruritus for greater than 6 months. The overall mean ± SD
GISQ score was 6.19 ± 2.42 out of 10, and the overall
mean ± SD raw ItchyQoL score was 57.11 ± 21.06 out of
110. The Spearman rank coefficient (0.557, p < 0.0001)
and Pearson correlation coefficient (0.559, p < 0.0001)
showed a moderate correlation between raw ItchyQoL
and GISQ scores. The correlation coefficients for all 5
proposed band sets ranged from 0.428 to 0.574 (Pearson)
and 0.462 to 0.552 (Spearman). The ItchyQoL Band Set
and GISQ breakdown with the highest measures of correlation (Pearson = 0.574, Spearman = 0.552) demonstrated
a қ = –0.2714 and weighted қ = 0.5677. Thus the set of
ItchyQoL bands and corresponding levels of pruritusspecific HRQoL impairment are as follows: 0–30 (little),
31–50 (mild), 51–80 (moderate), and 81–110 (severe).
These bands are visualized in Fig. 1.
DISCUSSION
HRQoL instruments elucidate the burden that diseases
place on patients, but lack of information on the clinical
interpretation of HRQoL scores limits their clinical use
(11, 12). This pilot study attempts to address such a
gap by proposing a set of bands to aid in the clinical
interpretation of the previously validated ItchyQoL.
With these bands, we know that if an ItchyQoL raw
score stays within a band after treatment, say 79 to
60, even if the change was statistically significant, the
change would not be clinically significant (moderate
to moderate impairment).
The anchor-based technique was chosen for its validity
with short and relatively simple questionnaires (13, 14).
The sum of all ItchyQoL questions was chosen to derive
© 2015 The Authors. doi: 10.2340/00015555-1891
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In conclusion, the ItchyQoL, with the 3 constructs, is
a rich instrument capable of elucidating the symptomatic, functional, and emotional burden created by chronic
pruritus. Never intended as a substitute for ItchyQoL
construct scores, raw ItchyQoL bands add an additional
layer of interpretation of the information. The results
of this pilot study need to be validated with a larger,
more heterogeneous population, but provide an initial
means to monitor significant clinical improvement or
exacerbation of pruritus.
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Fig. 1. Relationship between the raw ItchyQoL score and the mean, median,
and mode of the Global Itch Severity Question (GISQ) score with proposed
banding scale (full-drawn line) of ItchyQoL scores.

the 10-point intervals for its simplicity. Using the raw
ItchyQoL scores is unique to the proposed ItchyQoL
bands. Currently, ItchyQoL scores are calculated by taking the mean of all 22 questions, but this was thought undesirable because it involves decimal points and smaller
band ranges, making bands more difficult to remember,
potentially resulting in decreased use. The raw ItchyQoL
score increases the range of values, but does not affect
the questionnaire’s presentation to the patient nor the
instrument’s psychometrics or validity. However, if the
discrepancy of using the raw score versus the original
mean scores proves to be a barrier, a future iteration can
be explored using the mean scores.
Limitations to this pilot study include the small size,
relatively homogeneous subject population, and single
recruitment location, thus potentially limiting the generalizability of the results. Future studies need to include
larger populations that involve both nonveteran men
and women, incorporating other age groups. Another
limitation is that our kappa coefficient shows only a
moderate agreement between our set of ItchyQoL bands
and the GISQ. This may be attributable to the small
number of subjects. Additionally, the GISQ gauges “itch
severity” during the last 7 days, and does not have the
multi-dimensionality of the 3-construct ItchyQoL. This
difference in complexity of the two instruments may
have contributed to the less than ideal kappa coefficient.
Nonetheless, the weighted kappa, demonstrated moderate
agreement despite the small numbers and thus supports
the potential of the ItchyQoL bands to assess patients’
level of impairment. In future expanded studies, it may
be simpler to use “little, mild, moderate, severe” as
categorical answers to GISQ in order to map the bands
and thus not need to guess the cut-off values; or to utilize
percentiles of the reported rather than the possible scores,
however a larger sample would be necessary.
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